VIA
BPMC

Virtus Investment Advisers’s Blueprint Medicines BPMC Stock Holding History

Virtus Investment Advisers’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,878
Closed -$343K – 446
2025
Q1 		$343K Buy
+3,878
New +$378K 0.09% 229
2024
Q3 		– Sell
-758
Closed -$81.7K – 345
2024
Q2 		$81.7K Hold
758
– – 0.07% 247
2024
Q1 		$71.9K Hold
758
– – 0.05% 261
2023
Q4 		$69.9K Sell
758
-1,189
-61% -$77K 0.05% 260
2023
Q3 		$97.8K Hold
1,947
– – 0.07% 224
2023
Q2 		$123K Hold
1,947
– – 0.08% 231
2023
Q1 		$87.6K Buy
1,947
+309
+19% +$13.9K 0.06% 253
2022
Q4 		$71.8K Sell
1,638
-6,369
-80% -$305K 0.05% 290
2022
Q3 		$528K Buy
+8,007
New +$514K 0.24% 79

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Virtus Investment Advisers's BPMC Position: Q2 2025 in Review

Virtus Investment Advisers sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 3,878 shares — an estimated $343K sold.

Virtus Investment Advisers first reported a position in BPMC in Q3 2022 and held it in 9 quarters. The position peaked at $528K in Q3 2022. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Virtus Investment Advisers reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Virtus Investment Advisers sold 3,878 Blueprint Medicines shares in Q2 2025, an estimated $343K.
  • Virtus Investment Advisers first reported a position in Blueprint Medicines in Q3 2022 and held it in 9 quarters.
  • Virtus Investment Advisers's Blueprint Medicines position peaked at $528K in Q3 2022.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Virtus Investment Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.